Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation

CD Wang, TK Gallaher and JC Shih

Department of Molecular Pharmacology and Toxicology, School of Pharmacy, University of Southern California, Los Angeles 90033.

Serotonin 5-hydroxytryptamine (5-HT)2 receptors are implicated in the etiology of mental disease and depression. Drugs that interact with the 5-HT2 receptor are used therapeutically to treat such illnesses, and their mechanisms of action are of great interest. In this study 5-HT2 receptor-ligand interactions were examined by site-directed mutagenesis in which three aspartic acid to asparagine mutants (Asn-120, Asn-155, and Asn-172) were created and expressed in NIH3T3 cells. The Asp-120 to asparagine mutant exhibited the same affinity for 125I-lysergic acid diethylamide (125I-LSD) as did the wild-type receptor and showed a decreased and GTP-insensitive binding affinity for the agonists 5-HT and (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane (approximately 10-fold) and the antagonists ketanserin and mianserin (approximately 10- fold) but not spiperone. The mutation also abolished agonist-stimulated formation of [3H]polyphosphoinositides (PI). The Asn-155 mutant showed reduced binding affinity for 125I-LSD (Kd, 2.8 nM versus 0.6 nM for the wild-type receptor) and had reduced affinity for agonists (approximately 30-fold) and for antagonists (14-75-fold). However, the Asn-155 receptor retained GTP sensitivity and the ability to stimulate PI formation. The Asn-172 mutant retained the wild-type Kd value for 125I-LSD, exhibited only approximately 5-fold reduced affinity for 5-HT and (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane while retaining GTP-sensitive agonist binding showed no change in affinity for ketanserin, and had a small decrease in mianserin and spiperone binding (approximately 6-fold). The Asn-172 receptor also retained the ability to form PI. These results indicate that Asp-120 is necessary for allosteric activation of the guanine nucleotide-binding protein. Asp- 155 is necessary for high affinity binding, probably by acting as a counterion for the amine group of the ligand. The different effects of the three mutations on ketanserin, mianserin, and spiperone binding affinity suggest that these antagonists may share overlapping but different binding domains. The information provided by this study may facilitate the design of therapeutic site-selective compound based on the structure of the 5-HT2 receptor.

Volume 43, Issue 6, pp. 931-940, 06/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				M. R. Braden, J. C. Parrish, J. C. Naylor, and D. E. Nichols Molecular Interaction of Serotonin 5-HT2A Receptor Residues Phe339(6.51) and Phe340(6.52) with Superpotent N-Benzyl Phenethylamine Agonists Mol. Pharmacol., December 1, 2006; 70(6): 1956 - 1964. [Abstract] [Full Text] [PDF]

				B. Li, N. M. Nowak, S.-K. Kim, K. A. Jacobson, A. Bagheri, C. Schmidt, and J. Wess Random Mutagenesis of the M3 Muscarinic Acetylcholine Receptor Expressed in Yeast: IDENTIFICATION OF SECOND-SITE MUTATIONS THAT RESTORE FUNCTION TO A COUPLING-DEFICIENT MUTANT M3 RECEPTOR J. Biol. Chem., February 18, 2005; 280(7): 5664 - 5675. [Abstract] [Full Text] [PDF]

				N. H. Moniri, D. Covington-Strachan, and R. G. Booth Ligand-Directed Functional Heterogeneity of Histamine H1 Receptors: Novel Dual-Function Ligands Selectively Activate and Block H1-Mediated Phospholipase C and Adenylyl Cyclase Signaling J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 274 - 281. [Abstract] [Full Text] [PDF]

				M. C. Clark, T. E. Dever, J. J. Dever, P. Xu, V. Rehder, M. A. Sosa, and D. J. Baro Arthropod 5-HT2 Receptors: A Neurohormonal Receptor in Decapod Crustaceans That Displays Agonist Independent Activity Resulting from an Evolutionary Alteration to the DRY Motif J. Neurosci., March 31, 2004; 24(13): 3421 - 3435. [Abstract] [Full Text] [PDF]

				B. J. Ebersole, I. Visiers, H. Weinstein, and S. C. Sealfon Molecular Basis of Partial Agonism: Orientation of Indoleamine Ligands in the Binding Pocket of the Human Serotonin 5-HT2A Receptor Determines Relative Efficacy Mol. Pharmacol., January 1, 2003; 63(1): 36 - 43. [Abstract] [Full Text] [PDF]

				P. Manivet, B. Schneider, J. C. Smith, D.-S. Choi, L. Maroteaux, O. Kellermann, and J.-M. Launay The Serotonin Binding Site of Human and Murine 5-HT2B Receptors. MOLECULAR MODELING AND SITE-DIRECTED MUTAGENESIS J. Biol. Chem., May 3, 2002; 277(19): 17170 - 17178. [Abstract] [Full Text] [PDF]

				D. A. Shapiro, K. Kristiansen, D. M. Weiner, W. K. Kroeze, and B. L. Roth Evidence for a Model of Agonist-induced Activation of 5-Hydroxytryptamine 2A Serotonin Receptors That Involves the Disruption of a Strong Ionic Interaction between Helices 3 and 6 J. Biol. Chem., March 22, 2002; 277(13): 11441 - 11449. [Abstract] [Full Text] [PDF]

				C. S. Nelson, M. Ikeda, H. S. Gompf, M. L. Robinson, N. K. Fuchs, T. Yoshioka, K. A. Neve, and C. N. Allen Regulation of Melatonin 1a Receptor Signaling and Trafficking by Asparagine-124 Mol. Endocrinol., August 1, 2001; 15(8): 1306 - 1317. [Abstract] [Full Text] [PDF]

				D. A. Shapiro, K. Kristiansen, W. K. Kroeze, and B. L. Roth Differential Modes of Agonist Binding to 5-Hydroxytryptamine2A Serotonin Receptors Revealed by Mutation and Molecular Modeling of Conserved Residues in Transmembrane Region 5 Mol. Pharmacol., November 1, 2000; 58(5): 877 - 886. [Abstract] [Full Text]

				D. Macdonald, N. Murgolo, R. Zhang, J. P. Durkin, X. Yao, C. D. Strader, and M. P. Graziano Molecular Characterization of the Melanin-Concentrating Hormone/Receptor Complex: Identification of Critical Residues Involved in Binding and Activation Mol. Pharmacol., July 1, 2000; 58(1): 217 - 225. [Abstract] [Full Text]

				K. Kristiansen, W. K. Kroeze, D. L. Willins, E. I. Gelber, J. E. Savage, R. A. Glennon, and B. L. Roth A Highly Conserved Aspartic Acid (Asp-155) Anchors the Terminal Amine Moiety of Tryptamines and Is Involved in Membrane Targeting of the 5-HT2A Serotonin Receptor But Does Not Participate in Activation via a "Salt-Bridge Disruption" Mechanism J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 735 - 746. [Abstract] [Full Text]

				U. Gether Uncovering Molecular Mechanisms Involved in Activation of G Protein-Coupled Receptors Endocr. Rev., February 1, 2000; 21(1): 90 - 113. [Abstract] [Full Text]

				C. Wu, E. J. Yoder, J. Shih, K. Chen, P. Dias, L. Shi, X.-D. Ji, J. Wei, J. M. Conner, S. Kumar, et al. Development and Characterization of Monoclonal Antibodies Specific to the Serotonin 5-HT2A Receptor J. Histochem. Cytochem., July 1, 1998; 46(7): 811 - 824. [Abstract] [Full Text]

				E. A. Thomas, M. J. Carson, M. J. Neal, and J. G. Sutcliffe Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide PNAS, December 9, 1997; 94(25): 14115 - 14119. [Abstract] [Full Text] [PDF]

				S. C. Sealfon, H. Weinstein, and R. P. Millar Molecular Mechanisms of Ligand Interaction with the Gonadotropin-Releasing Hormone Receptor Endocr. Rev., April 1, 1997; 18(2): 180 - 205. [Abstract] [Full Text]

				B. L. Roth, M. S. Choudhary, N. Khan, and A. Z. Uluer High-affinity Agonist Binding Is Not Sufficient for Agonist Efficacy at 5-Hydroxytryptamine2A Receptors: Evidence in Favor of a Modified Ternary Complex Model J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 576 - 583. [Abstract] [Full Text]

				Z.-L. Lu, C. A. Curtis, P. G. Jones, J. Pavia, and E. C. Hulme The Role of the Aspartate-Arginine-Tyrosine Triad in the m1 Muscarinic Receptor: Mutations of Aspartate 122 and Tyrosine 124 Decrease Receptor Expression but Do Not Abolish Signaling Mol. Pharmacol., February 1, 1997; 51(2): 234 - 241. [Abstract] [Full Text] [PDF]

				N. Almaula, B. J. Ebersole, D. Zhang, H. Weinstein, and S. C. Sealfon Mapping the Binding Site Pocket of the Serotonin 5-Hydroxytryptamine2A Receptor. Ser3.36(159) PROVIDES A SECOND INTERACTION SITE FOR THE PROTONATED AMINE OF SEROTONIN BUT NOT OF LYSERGIC ACID DIETHYLAMIDE OR BUFOTENIN J. Biol. Chem., June 21, 1996; 271(25): 14672 - 14675. [Abstract] [Full Text] [PDF]

				S. C. Sealfon, L. Chi, B. J. Ebersole, V. Rodic, D. Zhang, J. A. Ballesteros, and H. Weinstein Related Contribution of Specific Helix 2 and 7 Residues to Conformational Activation of the Serotonin 5-HT[IMAGE] Receptor J. Biol. Chem., July 14, 1995; 270(28): 16683 - 16688. [Abstract] [Full Text] [PDF]